Company Legal Name
Latest Valuation
Founded Year
Headquarter
Rakuten Medical develops innovative cancer therapy technology that combines targeted drugs with light-activated devices to selectively destroy cancer cells. Based in San Diego, the company has pioneered a unique photoimmunotherapy approach that represents a novel treatment modality in oncology. This precision medicine platform offers the potential to target tumors while minimizing damage to healthy tissue, addressing a critical need in cancer treatment. Rakuten Medical's technology platform differentiates it from traditional chemotherapy and radiation approaches through its selective cell destruction mechanism. The company continues to advance its photoimmunotherapy solutions through clinical development and regulatory pathways.
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.
